Coherus completes divestiture of ophthalmology franchise


The company has divested its Coherus Ophthalmology subsidiary to Sandoz, Inc. for upfront all-cash consideration of $170 million.

(Image credit: AdobeStock/SITTIPONG)

(Image credit: AdobeStock/SITTIPONG)

Coherus BioSciences Inc announced the completion of the previously announced divestiture of its CIMERLI (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz, Inc for upfront all-cash consideration of $170 million.

According to a news release, included in the divesture is Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams, and access to proprietary commercial software.1

Denny Lanfear, chairman and CEO of Coherus, noted in the company’s news release the divesture allows the company to focus its business on advancing its novel immuno-oncology pipeline.

“Completion of this transaction allows us to pay down debt, reduce interest costs, reduce headcount and overhead costs, thereby significantly advancing our efforts to become a sustainable and growing oncology business,” he said in the release.

The company noted in the news release its oncology assets include the UDENYCA (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; LOQTORZI (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor. The company also has a diversified immuno-oncology pipeline with drug candidates with distinctive targets designed to inhibit immune suppressive mechanisms in the tumor microenvironment.1

Coherus received upfront, all-cash consideration of $170 million plus certain purchase price adjustments, which will be finalized following the closing pursuant to the agreement between Coherus and Sandoz.

J.P. Morgan Securities LLC acted as the company’s financial advisor, and Latham & Watkins LLP acted as legal counsel to Coherus in connection with the transaction.1

  1. Inc CB. Coherus Completes Divestiture of Ophthalmology Franchise. GlobeNewswire News Room. Published March 4, 2024. Accessed March 5, 2024.
Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.